Current Status of Drug Discovery and Development Through Targeted Protein Degradation
Drug Delivery System · 25.03.2026 · 41 (2) · 96-105
DOI: 10.2745/dds.41.96 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery System, erschienen am 25.03.2026. Verfasst von Tomoya Shiro. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
In recent years, drug discovery research utilizing targeted protein degradation (TPD), which enables the selective elimination of specific intracellular and extracellular proteins, has attracted considerable attention. Compounds that induce TPD leverage multiple degradation mechanisms within the endogenous cellular proteasome and lysosome pathway. Among these, the clinical application of chimeric degraders represented by PROTACⓇ (Proteolysis Targeting Chimera) has advanced rapidly in recent years, approaching the stage of social implementation. However, during the clinical development process, several common challenges related to physicochemical properties and pharmacokinetics for practical application have also emerged. This article provides an overview of TPD technologies followed by the current status of clinical trials for chimeric degraders and discusses the issues that have emerged so far and future prospects for overcoming them.
Zitieren
APA
Shiro, T. (2026). Current Status of Drug Discovery and Development Through Targeted Protein Degradation. Drug Delivery System, 41(2), 96-105. https://doi.org/10.2745/dds.41.96
Vancouver
Shiro T. Current Status of Drug Discovery and Development Through Targeted Protein Degradation. Drug Delivery System. 2026;41(2):96-105. doi:10.2745/dds.41.96
BibTeX
@article{Shiro2026,
author = {Shiro, Tomoya},
title = {Current Status of Drug Discovery and Development Through Targeted Protein Degradation},
journal = {Drug Delivery System},
year = {2026},
volume = {41},
number = {2},
pages = {96--105},
doi = {10.2745/dds.41.96}
}
EUVIMED